Clinical Trials | Research Study of Neoadjuvant treatment with zanzalintinib for advanced thyroid cancer

The University of Virginia Comprehensive Cancer Center seeks adults ages 18 and older with advanced thyroid cancer for a research study. The purpose of the study is to find out how safe and effective an investigational drug called Zanzalintinib is, followed by surgery. You may be eligible for this study if you have differentiated thyroid cancer, non-RET-mutated medullary thyroid cancer, or poorly differentiated thyroid cancer. This study involves taking an investigational drug and attending clinic visits that include physical exams, blood draws, heart scans, imaging scans, urine tests, and questionnaires. The study consists of coming to the clinic 1-2 times a month for study visits for about 6 months, followed by surgery. Each visit will last between 2 to 3.5 hours. Study-related exams, tests and experimental medication provided at no cost. Participant’s insurance company will be billed for administration of the drugs and any other medication, tests and procedures done as part of your routine clinical care. Additional information can be found here: https://clinicaltrials.gov/study/NCT06959511 [email protected]